Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Procalcitonin for the prognosis of adverse events

a technology of procalcitonin and adverse events, applied in the field of clinical diagnostics, can solve the problem that the level of procalcitonin or fragments thereof is correlated with the risk of the subject suffering from an adverse even

Inactive Publication Date: 2012-06-14
BRAHMS GMBH
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a way to predict who will have an adverse event, like a heart attack or stroke, based on a sample of their blood. The method involves measuring a protein called procalcitonin and comparing it to a control group. If the procalcitonin level is higher in the sample from the person who will have an adverse event, it indicates a higher risk of that person. This can help doctors and researchers better understand who is at risk for these events and take appropriate action.

Problems solved by technology

Secondly, the level of procalcitonin or fragments thereof is correlated to a risk of the subject to suffer from an adverse event.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

examples

Study Population and Design

[0054]The study population was obtained from the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. The PREVEND study was designed to investigate prospectively the natural course of albuminuria and its relation to renal and cardiovascular disease in a large cohort drawn from the general population (age ranged between 28 and 75 years) of the city of Groningen, the Netherlands. Details of the study design, recruitment, and procedures have been published elsewhere (Hiliege et al., Circulation 2002, 106:1777-1782; Hillege et al., J Intern Med 2001, 249:519-526; Mahmoodi et al., JAMA 2009, 301:1790-1797). The PREVEND study was approved by the local medical ethics committee, University Medical Center Groningen, and conformed to the principles outlined in the Declaration of Helsinki. All participants gave written informed consent.

Measurements

[0055]The participants underwent two outpatient visits to assess demographic, anthropometric, and cardiovas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
volumeaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk of sustaining an adverse event.

Description

FIELD OF THE INVENTION[0001]The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the determination of the level of Procalcitonin (PCT) in a sample derived from a bodily fluid of a subject.BACKGROUND OF THE INVENTION[0002]Procalcitonin (PCT) is known as a biomarker, that reflects the presence and severity of local and systemic bacterial infections, i.e. sepsis (Assicot et al., Lancet 1993; 341:515-8; Muller et al., Crit Care Med 2000; 28:977-83.; Harbarth et al., Am J Respir Crit Care Med 2001; 164:396-402; Becker et al., Crit Care Med 2008; 36:941-52; Becker et al., J Clin Endocrinol Metab 2004; 89:1512-25; Nobre et al., Am J Respir Crit Care Med 2008; 177:498-505; Christ-Crain et al., Lancet 2004; 363:600-7; Stolz et al., Chest 2007; 131:9-19; Christ-Crain et al., Am J Respir Crit Care Med 2006; 174:84-93; Briel et al., Arch Intern Med 2008; 168:2000-7; discussion 7-8).[0003]During bacterial infections, plasma PCT concentratio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/53
CPCG01N33/6893G01N2333/585G01N2800/50G01N2800/2871G01N2800/324G01N2800/042
Inventor STRUCK, JOACHIMBAKKER, S.J.L.
Owner BRAHMS GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com